Response
We appreciate the cogent observations and comments of Parolari et al regarding our recent analysis 1 from the STS National Cardiac Database of over 200 000 patients undergoing coronary artery bypass surgery (CABG) during a 2-year period. As the authors imply, in the hierarchy of clinical investigation, the large, prospective, randomized trial holds the highest order of evidence. Yet 8 years after the introduction of beating-heart surgery into routine clinical practice, only 5 randomized, singlecenter trials comparing on-pump and off-pump CABG have been completed, enrolling fewer than 1400 patients cumulatively. Furthermore, only one multicenter, randomized study of 2200 patients is currently underway in the United States (Veteran's Administration). With enrollment only 35% complete, it will be many years before outcomes evidence is available.
The next tool of clinical investigation in the hierarchy of outcomes study is the retrospective analysis of large outcomes databases using propensity score computer matching to correct for selection bias, as was done in our study. 1 This has been referred to as "randomization after the fact." We concur with Parolari et al and acknowledge that there are limitations inherent to this analysis as a result of unreported or indeterminate variables in the database and lack of prospective randomization. Despite these limitations, it provides the advantage of more rapid evaluation of outcomes in a larger number of patients who are more representative of "real-world" CABG surgery than those selected to meet the inclusion criteria of a randomized trial.
A large, prospective, randomized clinical trial comparing off-pump and on-pump coronary artery bypass has not been forthcoming and, if completed, will also have significant inherent limitations. Indeed, such a clinical trial could not be justified without conclusive supporting data from large, retrospective comparisons such as this one. We disagree that the data in this study are not conclusive. To the contrary, the differences in outcomes are indeed not small but highly significant according to sophisticated statistical analyses.
The hypothetical trial referred to by the authors is neither underway nor planned in the foreseeable future. Until this can be completed, large (Ͼ16 000 patients per treatment group compared in this study), retrospective, "randomized" comparisons based on propensity matching and risk stratification to account for selection bias offer the next best available data for evidencebased practice and add valuable information to the complex process of evaluating surgical procedures.
